Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow’s transitional pass-through ...
Harrow annonce le statut de remboursement transitoire de TRIESENCE (suspension injectable d'acétonide de triamcinolone) 40 mg/mL
Harrow a annoncé que les Centers for Medicare & Medicaid Services ont approuvé la demande de prise en charge transitoire de ...
Scientific Research Publishing13d
A Review of the Research Progress and Application of Skin Care Ointments in Chronic Eczema Treatment ()
A Review of the Research Progress and Application of Skin Care Ointments in Chronic Eczema Treatment ...
Scientific Research Publishing1mon
Kovacs, K., Wagley, S., Quirk, M.T., Ceron, O.M., Silva, P.A., Singh, R.J.,
ABSTRACT: The rapid development of artificial intelligence (AI) technology is profoundly reshaping all walks of life, especially in the medical field. AI provides innovative tools for medical ...